Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2025-12-25 @ 9:29 PM
Study NCT ID:
NCT05253651
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2022-02-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-10-24
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-07-27
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-14
First Submit QC Date:
None
Study First Post Date:
2022-02-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-10
Last Update Post Date:
2025-12-17
Last Update Post Date Type:
ESTIMATED